Charm and hidden charm scalar mesons in the nuclear medium

We study the renormalization of the properties of low lying charm and hidden charm scalar mesons in a nuclear medium, concretely of the D_{s0}(2317) and the theoretical hidden charm state X(3700). We find that for the D_{s0}(2317), with negligible width at zero density, the width becomes about 100 MeV at normal nuclear matter density, while in the case of the X(3700) the width becomes as large as 200 MeV. We discuss the origin of this new width and trace it to reactions occurring in the nucleus, while offering a guideline for future experiments testing these changes. We also show how those medium modifications will bring valuable information on the nature of the scalar resonances and the mechanisms of the interaction of D mesons with nucleons and nuclei

Identification of a novel 2-oxindole fluorinated derivative as in vivo antitumor agent for prostate cancer acting via AMPK activation

The key metabolic sensor adenosine monophosphate-dependent kinase (AMPK) has emerged as a promising therapeutic target for cancer prevention and treatment. Besides its role in energy homeostasis, AMPK blocks cell cycle, regulates autophagy and suppresses the anabolic processes required for rapid cell growth. AMPK is especially relevant in prostate cancer in which activation of lipogenic pathways correlate with tumor progression and aggressiveness. This study reports the discovery of a new series of 2-oxindole derivatives whose AMPK modulatory ability, as well as the antitumoral profile in prostate cancer cells, was evaluated. One of the assayed compounds, compound 8c, notably activated AMPK in cultured PC-3, DU145 and LNCaP prostate cancer cells. Likewise, compound 8c caused PC-3, DU145 and LNCaP cells viability inhibition. Selective knocking down of α1 or α2 isoforms as well as in vitro assays using human recombinant α1β1γ1 or α2β1γ1 AMPK isoforms revealed that compound 8c exhibit preference for AMPKα1. Consistent with efficacy at the cellular level, compound 8c was potent in suppressing the growth of PC-3 xenograft tumors. In conclusion, our results show that a new 2-oxindole fluorinated derivative exerts potent in vivo antitumor actions against prostate cancer cells, indicating a promising clinical therapeutic strategy for the treatment of androgen-independent prostate cancer.The authors would like to thank the Spanish Ministry of Economy and Competitiveness (Grant n° BFU2012- 31444; CTQ2010-19690); Junta de Comunidades Castilla-LaMancha and Fondo Europeo de Desarrollo Regional (FEDER) (Grant n° POII11-0159-0054); Comunidad de Madrid (Grant S2010-BMD2308); and the Fundación Tatiana Pérez de Guzmán el Bueno (Grant n° Patrocinio 2013-001) for financial support into their research. S.Q. is the recipient of a fellowship (Grant JAE-Pre-2011) from Junta para la Ampliación de Estudios cofinanced by Fondo Socio Europeo (FSE).Peer Reviewe

Prospects for dark matter observations in dwarf spheroidal galaxies with the Cherenkov Telescope Array Observatory

International audienceThe dSphs around the Milky Way are commonly considered as systems that are supported by velocity dispersion against self-gravitation. They have been long accounted among the best targets to search for indirect DM signatures in the GeV-to-TeV gamma-rays due to absence of astrophysical gamma-ray foreground or background emission. We present forecasts on the sensitivity of the future CTAO for the search for annihilating or decaying DM in such targets. We perform an original selection of candidates out of the current catalog of known objects, including both classical and ultra-faint targets. For each of them, we calculate the expected amount of DM using the most updated and complete available samples of photometric and spectroscopic data of member stars, adopting a common framework of data treatment for both classes of objects. In this way, we are able to generate novel astrophysical factor profiles for general indirect DM searches that we compare with the current literature. Out of a starting sample of 64 dSphs, we highlight the 8 most promising targets - DraI, CBe, UMaII, UMi and Wil1 in the Northern hemisphere; RetII, Scl and SgrII in the Southern hemisphere - for which different DM density models (either cored or cuspy) lead to similar expectations, at variance with what happens for other DM targets - thus resulting in more robust predictions. We find that CTAO will provide the strongest limits above ~10 TeV, down to values of velocity-averaged annihilation cross section of ~5$\times 10^{-25}$ cm$^3$ s$^{-1}$ and up to decay lifetimes of ~10$^{26}$ s for combined limits on the best targets. We argue that the largest source of inaccuracy is due to the still imprecise determination of the DM content, especially for ultra-faint dSphs. We propose possible strategies of observation for CTAO, either optimized on a deep focus on the best known candidates, or on the diversification of targets

Prospects for dark matter observations in dwarf spheroidal galaxies with the Cherenkov Telescope Array Observatory

International audienceThe dSphs around the Milky Way are commonly considered as systems that are supported by velocity dispersion against self-gravitation. They have been long accounted among the best targets to search for indirect DM signatures in the GeV-to-TeV gamma-rays due to absence of astrophysical gamma-ray foreground or background emission. We present forecasts on the sensitivity of the future CTAO for the search for annihilating or decaying DM in such targets. We perform an original selection of candidates out of the current catalog of known objects, including both classical and ultra-faint targets. For each of them, we calculate the expected amount of DM using the most updated and complete available samples of photometric and spectroscopic data of member stars, adopting a common framework of data treatment for both classes of objects. In this way, we are able to generate novel astrophysical factor profiles for general indirect DM searches that we compare with the current literature. Out of a starting sample of 64 dSphs, we highlight the 8 most promising targets - DraI, CBe, UMaII, UMi and Wil1 in the Northern hemisphere; RetII, Scl and SgrII in the Southern hemisphere - for which different DM density models (either cored or cuspy) lead to similar expectations, at variance with what happens for other DM targets - thus resulting in more robust predictions. We find that CTAO will provide the strongest limits above ~10 TeV, down to values of velocity-averaged annihilation cross section of ~5$\times 10^{-25}$ cm$^3$ s$^{-1}$ and up to decay lifetimes of ~10$^{26}$ s for combined limits on the best targets. We argue that the largest source of inaccuracy is due to the still imprecise determination of the DM content, especially for ultra-faint dSphs. We propose possible strategies of observation for CTAO, either optimized on a deep focus on the best known candidates, or on the diversification of targets

Impact of COVID-19 on Cardiovascular Testing in the United States Versus the Rest of the World

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-U.S. institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection